Yoji Hakamata

Prof. Dr. Yoji Hakamata

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KSKazuhisa Sugai
Kazuhisa Sugai
TTTomoyoshi Tamura
Tomoyoshi Tamura
MSMotoaki Sano
Motoaki Sano
SUShizuka Uemura
Shizuka Uemura
MFMasahiko Fujisawa
Masahiko Fujisawa
YHYoji Hakamata
Yoji Hakamata
A recent clinical study demonstrated that haemodialysis with a dialysate containing hydrogen (H2) improves blood pressure control in end-stage kidney disease. Herein, we examined whether H2 has a salutary effect on hypertension in animal models. We subjected 5/6 nephrectomised rats to inhalation of either H2 (1.3% H2 + 21% O2 + 77.7% N2) or control (21% O2 + 79% N2) gas mixture for 1 h per day. H2 significantly suppressed increases in blood pressure after 5/6 nephrectomy. The anti-hypertensive effect of H2 was also confirmed in rats in a stable hypertensive state 3 weeks after nephrectomy. To examine the detailed effects of H2 on hypertension, we used an implanted telemetry system to continuously monitor blood pressure. H2 exerted an anti-hypertensive effect not only during daytime rest, but also during night-time activities. Spectral analysis of blood pressure variability revealed that H2 improved autonomic imbalance, namely by suppressing the overly active sympathetic nervous system and augmenting parasympathetic nervous system activity; these effects co-occurred with the blood pressure-lowering effect. In conclusion, 1-h daily exposure to H2 exerts an anti-hypertensive effect in an animal model of hypertension.

1 November 2000 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YIYutaka Inokiab
Yutaka Inokiab
YHYoji Hakamata
Yoji Hakamata
THToshiro Hamamotoa
Toshiro Hamamotoa
TKTadatoshi Kinouchia
Tadatoshi Kinouchia
SYShoji Yamazakia
Shoji Yamazakia
HEHitoshi Endo
Hitoshi Endo

1 October 2000 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Open access
PDF file
MKMinoru Kobayashi
Minoru Kobayashi
HTHideto To
Hideto To
MYMasayuki Yuzawa
Masayuki Yuzawa
YHYoji Hakamata
Yoji Hakamata
SHShun Higuchi
Shun Higuchi
EKEiji Kobayashi
Eiji Kobayashi
Renal dysfunction induced by a single injection of cisplatin depends on the timing of the dose. However, the effects of repeated administration of cisplatin on time-dependent toxicity have not been evaluated despite the fact that in clinical practice high doses are repeatedly injected at intervals or low doses are administered daily. We studied chrono-nephrotoxicity in rats after weekly or daily cisplatin injections.Weekly high doses (5 mg kg−1) or daily low doses (1.2 mg kg−1) of cisplatin were injected at four time points (3, 9, 15 and 21 h after the light was turned on (HALO)) for 3 weeks. Changes in body weight after weekly cisplatin administration were independent of the timing of the doses. In the group that received daily cisplatin, the loss in body weight in the 3 HALO group was smaller than in animals receiving injections at 15 and 21 HALO (P < 0.05 and 0.001, respectively). The blood urea nitrogen and serum creatinine levels in the control rats showed a significant circadian change (peak at 15 HALO and trough at 9 HALO), but these parameters were markedly elevated in both trials and their circadian variations were disturbed. In conclusion, cisplatin-induced nephrotoxicity was the lowest at 3HALO compared with other time points of both dose regimens.

1 April 2003 in Journal of Histochemistry & Cytochemistry
Verified
Journal Article
Open access
PDF file
MTMasafumi Takahashi
Masafumi Takahashi
YHYoji Hakamata
Yoji Hakamata
KTKoichi Takeuchi
Koichi Takeuchi
EKEiji Kobayashi
Eiji Kobayashi

27 December 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MHMomoko Hirano
Momoko Hirano
KSKazuhisa Sugai
Kazuhisa Sugai
MFMasahiko Fujisawa
Masahiko Fujisawa
EKEiji Kobayashi
Eiji Kobayashi
YKYoshinori Katsumata
Yoshinori Katsumata
MSMotoaki Sano
Motoaki Sano
Intraperitoneal administration of hydrogen (H2)-containing saline inhibited neuronal cell death in ischemic stroke in a number of animal models, but it is unknown whether H2 is absorbed from the abdominal cavity into the blood and reaches the brain. In this study, we investigated whether intraperitoneal administration of saline containing H2 inhibits neuronal cell death caused by cerebral ischemia and measured the concentration of H2 in the carotid artery and inferior vena cava (IVC). Gerbils were subjected to transient unilateral cerebral ischemia twice, and saline or H2-rich saline was administered intraperitoneally three or seven times every 12 hours. We evaluated the number of apoptotic cells in the hippocampus and cerebral cortex on day 3 and the number of viable neurons in the hippocampus and cerebral cortex on day 7. In addition, a single dose of saline or H2-rich saline was administered intraperitoneally, and blood H2 levels in the carotid artery and IVC were measured. On day 3 of ischemia/reperfusion, the number of neurons undergoing apoptosis in the cortex was significantly lower in the H2-rich saline group than in the saline group, and on day 7, the number of viable neurons in the hippocampus and cerebral cortex was significantly higher in the H2-rich saline group. Intraperitoneal administration of H2-rich saline resulted in large increases in H2 concentration in the IVC ranging from 0.00183 mg/L (0.114%) to 0.00725 mg/L (0.453%). In contrast, carotid H2 concentrations remained in the range of 0.00008 mg/L (0.0049%) to 0.00023 (0.0146%). On average, H2 concentrations in carotid artery were 0.04 times lower than in IVC. These results indicate that intraperitoneal administration of H2-rich saline significantly suppresses neuronal cell death after cerebral ischemia, even though H2 hardly reaches the brain.

28 October 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
AOAsahi Oda
Asahi Oda
YHYoji Hakamata
Yoji Hakamata
EKEiji Kobayashi
Eiji Kobayashi
Blackberries are abundant in substances that have antioxidative and other effects, and technologies for enhancing the effectiveness of their incorporation into the body are being developed. The effectiveness of such substances has been investigated in various models, including rodent ischemia models. While a test substance can be administered either before or after an event, healthy foods are generally pre-administered prophylactically in experiments. Pre-administration may have the potential to elevate the blood concentration of the active substance sufficiently prior to the event and/or induce adaptive changes in the ischemic tolerance of the recipient through long-term pre-administration. Based on the recently reported 2-week pre-administration of blackberries in a rat model, we investigated the pre-administration of blackberry extracts in a hyperlipidemia model using Mongolian gerbils. We then discussed the effects of the pre-administration on the treated animals before an ischemic event.